For European medical device companies, entering the US market often requires adjusting to a different regulatory system.
The FDA pathway has its own terminology, submission routes, inspection expectations, and post-market requirements. Even companies with mature EU processes and ISO 13485-certified quality management systems need to understand how those systems translate into the US regulatory environment.
With FDA’s Quality Management System Regulation, or QMSR, now in effect, this connection has become more direct.
The QMSR became effective on 2 February 2026 and amended the FDA’s current good manufacturing practice requirements under 21 CFR Part 820 by incorporating ISO 13485:2016 by reference. The purpose is to harmonise FDA’s device quality system requirements more closely with the quality management system standard already widely used by medical device manufacturers internationally.
For companies already working under ISO 13485, this is an important development. However, it does not mean that FDA compliance becomes automatic.
A more familiar foundation for ISO 13485 companies
The move from the previous Quality System Regulation, often referred to as QSR, to QMSR creates a more familiar quality system foundation for many European manufacturers.
ISO 13485 is already central to medical device quality management in Europe and many other markets. By incorporating ISO 13485:2016 into Part 820, FDA has moved closer to a structure that global manufacturers are likely to recognise.
This can make US market planning more understandable for companies that already have an established ISO 13485 quality management system.
Many core quality system topics will feel familiar: management responsibility, risk-based thinking, design and development controls, supplier management, production and service provision, complaint handling, corrective and preventive action, and document and record control.
That familiarity is useful. It means companies do not necessarily need to think of the US quality system as entirely separate from their existing QMS.
But it also requires careful interpretation.
ISO 13485 certification is not the same as FDA readiness
Although QMSR incorporates ISO 13485, companies should not assume that ISO 13485 certification alone is sufficient for FDA compliance.
FDA-regulated manufacturers still need to meet applicable FDA requirements. The QMSR applies to finished device manufacturers that intend to commercially distribute medical devices in the United States, and FDA expects manufacturers to establish and follow the relevant quality management system requirements.
This distinction matters.
A quality system may be ISO 13485-certified and still need review against FDA-specific expectations, terminology, records, inspection practices, reporting obligations, and US regulatory context. The practical question is not only whether a QMS exists, but whether it supports the way FDA will assess the manufacturer.
For European companies, this is where a structured gap assessment can be useful. It helps identify which parts of the existing QMS already align well and where additional FDA-specific adjustments may be needed.
Inspection expectations have also changed
The QMSR also affects how FDA inspections are approached.
On 2 February 2026, FDA began using the updated inspection process described in the revised Inspection of Medical Device Manufacturers Compliance Program. FDA also stopped using the previous Quality System Inspection Technique, or QSIT, for device inspections from that date.
This means companies preparing for FDA inspection should not only look at the text of the regulation. They should also consider how their quality system, records, and processes will be presented during inspection.
FDA’s own FAQ recommends that firms be prepared to discuss and provide records that demonstrate compliance with QMSR requirements during inspections occurring on or after the effective date.
In practice, this reinforces a familiar point: procedures alone are not enough. Companies need records and evidence showing that the system is implemented and maintained.
What European companies should review
For companies already operating under ISO 13485, QMSR readiness should usually begin with a practical comparison between the existing QMS and FDA expectations.
This may include reviewing how design and development activities are documented, how risk management is integrated into the development process, how suppliers are qualified and controlled, how complaints are handled, and how CAPA processes are implemented.
It may also include reviewing records, terminology, responsibilities, traceability, and links to FDA-specific obligations outside the quality system itself.
For companies preparing a 510(k), De Novo, Q-Submission, or broader US market entry strategy, this review should not be left until after the submission work is already well advanced. Quality system readiness, technical documentation, regulatory strategy, and post-market planning should support each other.
Why QMSR matters for US market entry
For European companies, FDA strategy is often discussed mainly through submission pathways.
The focus is commonly on whether the device fits a 510(k), De Novo, or PMA route, whether a suitable predicate exists, what evidence is needed, and whether early FDA interaction through a Q-Submission would be valuable.
Those questions remain important.
However, QMSR highlights that US market entry is not only a submission question. It is also a quality system readiness question.
A company may have a promising regulatory pathway, but still need to ensure that its QMS, records, post-market processes, and inspection readiness are aligned with FDA expectations. This is especially important for companies that are already established in Europe and are now adapting existing systems for the US market.
Avoiding parallel systems where possible
One of the practical opportunities created by QMSR is the possibility of building a more integrated quality system.
For global manufacturers, maintaining separate quality systems for different markets can create duplication, inconsistency, and unnecessary administrative burden. Since QMSR incorporates ISO 13485, companies may be able to build on an existing ISO 13485-based system and adapt it to address FDA-specific requirements.
This approach can support efficiency, but it needs to be done carefully.
The goal should not be to assume full equivalence between EU and US expectations. Instead, companies should identify common foundations, map the differences, and build a quality system that can support both regulatory environments in a controlled way.
How MDS supports QMSR readiness
At MDS, QMSR readiness is approached as a practical quality and regulatory alignment exercise.
For companies already operating under ISO 13485, this can begin with a gap assessment to compare the existing QMS against FDA expectations under QMSR. From there, the work may include updating procedures, strengthening records, clarifying responsibilities, preparing for inspection expectations, and aligning quality system processes with FDA submission and post-market requirements.
For companies planning US market entry, QMSR should be considered alongside broader FDA strategy. This includes regulatory pathway assessment, Q-Submission planning, technical documentation, clinical and performance evidence, and post-market obligations.
The aim is to help companies avoid treating FDA quality system requirements as a separate issue that only becomes relevant later.
Moving forward with a clearer view
The introduction of QMSR is an important step toward greater international alignment in medical device quality management.
For European companies, this creates a more familiar starting point because ISO 13485 is already part of their regulatory and quality management environment. But familiarity should not be mistaken for automatic readiness.
The companies best positioned for US market entry are those that understand both sides: the ISO 13485 foundation they already have, and the FDA-specific expectations that still need to be addressed.
If your organisation is planning US market entry or reviewing its quality system under FDA QMSR, MDS can support your team with gap assessments, QMS updates, FDA strategy, submission planning, and practical inspection readiness.
You can contact us at sales@mdsfinland.com or via Book a Meeting.
